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Introduction
Persistent immune activation and inflammation are hallmarks of 
chronic HIV/SIV infection and strong predictors of disease pro-
gression, independent of plasma viral loads (pVLs), or peripheral 
CD4+ T cell counts (1). They also persist in individuals with HIV/
SIV and nonhuman primates (NHPs) on antiretroviral therapy 
(ART), predicting poor immune restoration, accelerated aging, and 
development of non–AIDS-associated comorbidities (2–5). The 
mechanisms of HIV/SIV-associated immune activation and inflam-
mation are the subject of intense research, with key determinants 
including persistent virus replication, coinfections, dysregulation 
of T cell homeostasis, and microbial translocation (4, 6–8). Mean-
while, other unknown factors likely contribute to HIV/SIV-associ-
ated chronic immune activation and inflammation. Among these, 
dietary habits may affect inflammation through multiple pathways 
(9), altering the pathogenesis of chronic HIV/SIV infection. Little is 
known, however, with regard to these effects.
Consuming a high-fat diet (HFD) is a leading risk factor for 
obesity and type 2 diabetes (10), which are both characterized by 
chronic inflammation (10), marked by elevated TNF-α, IL-1, IL-6, 
and accumulation of proinflammatory macrophages in the adipose 
tissue (10). A HFD alters the gastrointestinal (GI) mucosa, disrupts 
gut microbiota, and induces intestinal damage. These conditions 
all lead to microbial translocation (11–13), further boosting chronic 
immune activation and inflammation, thus accelerating HIV/SIV 
disease progression.
In humans, Western diets are associated with an increased risk 
of nonalcoholic fatty liver disease (NAFLD) (14). The impact of 
Western diet on liver health is discernible within weeks (15). In the 
United States, NAFLD became a significant health problem in male 
adolescents who frequently consume Western diets (15). HFD can 
also induce NAFLD in mice and rats, along with significant eleva-
tion in TNF-α, NF-κB, and oxidative stress. These liver alterations 
correlate with thickening of the carotid intima (16), suggesting a 
possible connection between liver pathology and cardiovascular 
(CV) disease. In humans, through elevated inflammation via the 
TLR4/NF-κB signaling pathway, HFD causes renal, retinal, and 
brain function impairments (17). As liver, renal, and neurological 
disorders are also common HIV-associated comorbidities, HFD 
may increase the risk for or the severity of HIV comorbidities.
Consuming a high-fat diet (HFD) is a risk factor for obesity and diabetes; both of these diseases are also associated 
with systemic inflammation, similar to HIV infection. A HFD induces intestinal dysbiosis and impairs liver function and 
coagulation, with a potential negative impact on HIV/SIV pathogenesis. We administered a HFD rich in saturated fats and 
cholesterol to nonpathogenic (African green monkeys) and pathogenic (pigtailed macaques) SIV hosts. The HFD had a 
negative impact on SIV disease progression in both species. Thus, increased cell-associated SIV DNA and RNA occurred in 
the HFD-receiving nonhuman primates, indicating a potential reservoir expansion. The HFD induced prominent immune cell 
infiltration in the adipose tissue, an important SIV reservoir, and heightened systemic immune activation and inflammation, 
altering the intestinal immune environment and triggering gut damage and microbial translocation. Furthermore, HFD altered 
lipid metabolism and HDL oxidation and also induced liver steatosis and fibrosis. These metabolic disturbances triggered 
incipient atherosclerosis and heightened cardiovascular risk in the SIV-infected HFD-receiving nonhuman primates. Our study 
demonstrates that dietary intake has a discernable impact on the natural history of HIV/SIV infections and suggests that 
dietary changes can be used as adjuvant approaches for HIV-infected subjects, to reduce inflammation and the risk of non-
AIDS comorbidities and possibly other infectious diseases.
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fected NHP species. HFD also significantly increased systemic 
immune activation and inflammation and altered the gut mucosal 
environment, profoundly compromising gut integrity and increas-
ing microbial translocation. Furthermore, HFD induced liver ste-
atosis, fibrosis, and alterations of the lipid metabolism. Finally, 
HFD increased frequency and severity of CV lesions. Altogether, 
our results provide strong evidence for the critical role of HFD in 
modulating HIV/SIV morbidity and mortality.
Results
Study design. We used a diet that provided 32% calories from fat 
(Table 1), as opposed to normal chow, which only provides 13% 
calories from fat (Table 1). The composition of the HFD we used 
closely mimicked that of a typical American diet for the high con-
tent of saturated fats and cholesterol (23).
HFD was administered to 2 NHP models of nonpathogenic 
(AGM) and pathogenic (PTM) SIV infection. The goal was not to 
compare the HFD impact between species, but rather to assess the 
HFD consequences within the same species, as direct comparisons 
between species may be flawed by major intrinsic immunologic 
and metabolic differences. In the same line of reason, we did not 
perfectly match the timing of HFD administration in the 2 species.
Four AGMs received HFD from 102 days before infection and 
up to 200 days after infection (dpi) (Figure 1). One HFD-treated 
AGM died during the follow-up. The remaining 3 AGMs were 
released at the study completion. Nine historical control AGMs 
were used (Figure 1). They were SIV infected in similar condi-
tions, had a similar follow-up and sampling schedule to the 
AGMs receiving HFD, but received a regular chow diet (Table 1). 
The AGM historical controls were not subjected to intestinal and 
liver resections.
Five PTMs received HFD from 39 days before SIV infection 
until they progressed to AIDS (Figure 1). Ten PTMs were used as 
controls (Figure 1). They were SIV infected in similar conditions 
but received a regular chow diet (Table 1). Three PTMs were con-
temporary controls and had a follow-up and sampling schedule 
similar to that for HFD-receiving PTMs (including intestinal and 
liver resections). They either progressed to AIDS or were eutha-
nized when the last HFD-receiving PTM died with AIDS. The 
remaining 7 PTMs were historical controls. They had a follow-up 
and sampling schedule similar to that for HFD-receiving PTMs, 
but were not subjected to intestinal and liver resections. They were 
euthanized when they progressed to AIDS. All controls received 
the same chow diet.
HFD has a major impact on disease progression and survival of 
SIV-infected NHPs. First, we questioned whether HFD affected key 
parameters of HIV/SIV infection (i.e., CD4+ T cell counts and pVLs).
Peripheral CD4+ T cell loss was significantly more prominent 
in the SIVsab-infected AGMs receiving HFD compared with con-
trols. As such, although a trend toward recovery was observed 
during chronic infection, the CD4+ T cell counts were still sig-
nificantly lower in HFD-receiving AGMs compared with controls 
(Figure 2A). Interestingly, a CD4+ T cell decrease trend occurred 
in AGMs after HFD administration even before SIV infection, 
which was not due to CD4+ T cell downregulation (24), as no 
increases in the CD8-αlow or CD4negCD8neg T cells were observed 
in the HFD-treated AGMs during the follow-up (data not shown).
Additionally, HFD is a classical risk factor for CV diseases. 
HFD induces atherosclerosis (18) by enhancing dyslipidemia and 
macrophage infiltration in the aorta (18). HFD also alters the coag-
ulation profiles and promotes hypercoagulopathy, by increasing 
plasma levels of endogenous thrombin and procoagulant factors 
(e.g., FII, FVII, FVIII, and FXII), or decreased fibrinolysis (19). 
Hypercoagulability is common in HIV/SIV infections and may 
contribute to residual immune activation and inflammation (20) 
even in individuals with ART suppression (2, 3). By altering the lip-
id metabolism and coagulation, HFD may thus enhance the inci-
dence of CV comorbidities, the most frequent complications, and 
the leading cause of mortality in HIV-infected subjects (21).
As such, HFD may significantly affect the natural history of 
HIV/SIV, limit ART efficacy, promote HIV/SIV-related comorbid-
ities, and ultimately increase mortality (2, 3). Only 1 study previ-
ously reported accelerated disease progression in SIV-infected 
rhesus macaques receiving HFD (22). The underlying mecha-
nisms and the potential impact on SIV-related comorbidities were 
not investigated in detail, however, and only the model of patho-
genic HIV infection was evaluated.
To thoroughly assess the impact of HFD on HIV/SIV natural 
history and associated comorbidities, we conducted a compre-
hensive study in which we administered a HFD rich in saturated 
fats and cholesterol to 2 NHP models of SIVsab infection: Afri-
can green monkeys (AGMs), in which infection is nonpathogenic 
(i.e., lacking gut damage, immune activation and inflammation, 
comorbidities and disease progression) and pigtailed macaques 
(PTMs), in which infection is pathogenic (i.e., associating massive 
gut damage, immune activation and inflammation, comorbidities, 
progression to AIDS and death).
We report that HFD administration had a major impact on 
viral reservoir seeding and disease progression in both SIV-in-
Table 1. Comparison of ND and HFD composition
ND HFD
CompositionA
Fat, % 5.0 15.2
Cholesterol, ppm 80 946
Linoleic acid, % 1.46 3.02
Linolenic acid, % 0.09 0.09
Arachidonic acid, % <0.01 0.01
Omega-3 fatty acids, % 0.15 0.02
Total saturated fatty acids, % 1.36 6.05
Total monounsaturated fatty acids, % 1.72 4.85
Protein, % 15.6 18
Carbohydrates, % 60 55.6
Calories provided by
Protein, % 17.96 16.7
Fat, % 12.95 31.8
Carbohydrates, % 69.09 51.5
HFD, high-fat diet; ND, normal diet; ppm, parts per million. ANutrients 
are expressed as percentage of ration except where otherwise indicated. 
Moisture content is assumed to be 10.0% for the purpose of the calculations. 
Bolded values represent major differences between HFD and normal chow.
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(Figure 2I). AIDS-defining histological lesions also occurred earlier 
in HFD-receiving PTMs (Supplemental Table 1). At necropsy, the 
HFD-receiving PTMs presented with more lymphoid depletion, 
opportunistic infections, and macrophage infiltration in tissues 
compared with controls sacrificed at the same time points after 
infection. The CV lesions were also more severe in the HFD-receiv-
ing PTMs (Supplemental Table 2). Altogether, these features indi-
cate an early progression to AIDS and development of more severe 
SIV-related comorbidities in the HFD-treated animals.
Most strikingly, despite the nonpathogenic nature of SIVsab 
infection in AGMs, 1 HFD-receiving AGM died during follow-up 
(Figure 2J), with multiple biomarkers predicting HIV/SIV disease 
progression increasing in the range found in PTMs with end-stage 
disease: mucosal (Figure 3A) or systemic (Figure 3B) T cell activa-
tion, LPS (Figure 3C), hyaluronic acid (Figure 3D), soluble inter-
cellular adhesion molecule-1 (Figure 3E); and D-dimer (Figure 
3F). At necropsy, this AGM presented with lesions representative 
of AIDS (opportunistic infections) and SIV-related comorbidities: 
enteritis characterized by a severe disruption of the small intestine 
architecture with epithelial lesions (Figure 3G) and lamina propria 
infiltration with foamy cells (Figure 3H). Such sheets of foamy 
macrophages in the lamina propria are characteristic of atypical 
mycobacteria infection of the severely immunosuppressed hosts. 
Although the acid-fast staining could not identify the bacilli in the 
gut, occurrence of liver granulomas in this animal also support the 
diagnosis of atypical mycobacteria infection (Figure 3I).
Severe infiltrative cystoisosporiasis was also diagnosed in this 
AGM (Figure 3J) and confirmed through Giemsa staining (Figure 
3K). The lesions found in the intestinal epithelium and lamina pro-
pria are pathognomonic for infection with Cystoisospora belli (for-
HFD-receiving AGMs had higher plasma VLs, which reached 
significance during chronic infection (Figure 2B), along with signifi-
cantly higher PBMC-associated SIV DNA levels during acute infec-
tion (Figure 2C), suggesting that HFD may potentiate early reser-
voir seeding. This effect was confirmed on the gut samples from 
the HFD-receiving AGMs, in which acute proviral DNA (vDNA) 
levels (Figure 2D), along with acute and chronic viral RNA (vRNA) 
levels (Supplemental Figure 1A; supplemental material available 
online with this article; https://doi.org/10.1172/JCI121208DS1) 
were significantly higher than in controls. The acute vRNA levels 
were also higher in the lymph nodes (LNs) of the HFD-receiving 
AGMs than in controls (Supplemental Figure 1B).
In SIVsab-infected PTMs, which experience severe CD4+ T 
cell depletion throughout infection, HFD induced further sig-
nificant CD4+ T cell loss at late time points (Figure 2E). Neither 
pVLs nor PBMC or intestine cell-associated vDNA levels were 
significantly increased in the HFD-receiving PTMs compared 
with controls (Figure 2, F–H). We detected significantly higher 
cell-associated vRNA levels during chronic infection in both intes-
tine (Supplemental Figure 1C) and LNs (Supplemental Figure 1D) 
in the HFD-receiving PTMs, however, suggesting higher viral 
replication in tissues. Note that SIVsab-infected PTMs undergo 
massive viral replication and yield very high VLs (25), which likely 
masked the HFD effect on VL.
These data suggest that HFD increases virus replication, particu-
larly in tissues and may thus have an impact on the viral reservoir size.
HFD affected SIV survival in both species (Figure 2, I and J). 
Although the limited sample size precluded reaching statistical 
significance, there was a clear trend toward faster progression to 
AIDS in HFD-receiving PTMs compared with controls (P = 0.0522) 
Figure 1. The study design for SIVsab: HFD administration and sampling schedule. A total of 13 AGMs and 15 PTMs were infected with 300 TCID50 of 
SIVsab. Four AGMs initiated HFD at 102 days before infection and maintained it until 200 days after infection (dpi). Nine historical AGM controls were 
included and received normal chow. Five PTMs initiated HFD at 39 days before infection and maintained it until necropsy (128–218 days after infection). 
Three contemporary and 7 historical controls were also included and received normal chow. Sampling of the AGMs and PTMs in the study and control 
groups was performed as shown.
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tified in the colon by immunohistochemistry (Figure 3N, upper pan-
els). The CMV infection in the colon was also confirmed through 
PCR (Supplemental Figure 2). Large, sometimes multinucleated 
cells with viral cytoplasmic or nuclear inclusions surrounded by a 
clear halo (Figure 3N, lower panels) also indicative of CMV infection 
were present in the lung along with interstitial inflammation (Figure 
3O). CMV infection of the lung was confirmed by PCR (Supplemen-
tal Figure 2). The same technique identified CMV in the spleen and 
submandibular LNs (Supplemental Figure 2), and the virus could be 
quantified in blood (at 67 vDNA copies/mL of plasma), thus con-
firming the disseminated CMV infection.
Finally, chronic glomerulonephritis and thrombotic microan-
giopathy (TMA), that is, numerous microthrombi in the kidney and 
other tissues (Figure 3P), was also found in the AGM progressor. 
merly known as Isospora belli) and were identified, as usually done 
in a routine histopathological exam, using HE staining (Figure 
3J). Diverse evolutionary forms of the parasite were easily recog-
nizable in vacuoles located in the cytoplasm of the gut epithelial 
cells (Figure 3, J and K). The vacuoles containing the parasites 
were most frequently located under the host cells’ nuclei that were 
sometimes pushed horizontally creating the classical T-shape 
form. The parasites were associated with eosinophil infiltration in 
the lamina propria (Figure 3L). Cystoisosporiasis is an opportunis-
tic infection found in patients infected with HIV who have severe 
immunosuppression (26).
Furthermore, the AGM progressor also presented with colitis 
that associated crypt atrophy and infiltration of all intestinal layers 
with mononuclear cells (Figure 3M). CMV-positive cells were iden-
Figure 2. HFD accelerates disease progression and affects survival of SIV-infected NHPs. Peripheral CD4+ T cell depletion in SIV-infected AGMs (A) and 
PTMs (E) are shown as index of baseline levels and compared at key time points of SIV infection within HFD group with the Friedman test corrected for 
multiple comparisons and between HFD and control groups with Kruskal-Wallis test. Plasma viral loads (B), PBMC-associated viral DNA (C), and intes-
tinal cell-associated DNA (D) levels in SIV-infected AGMs, and in SIV-infected PTMs (F–H) were compared at acute and chronic infection between HFD 
and control groups with Kruskal-Wallis test. Data are presented as individual values with medians. Sample size (n) and P values are presented on graphs. 
BL, baseline (preinfection pre-HFD); Ac, acute infection; Chr, chronic infection; Fat, preinfection post-HFD; Nx, necropsy. Kaplan–Meier survival curves of 
SIV-infected PTMs (I) and AGMs (J) and PTMs are illustrated. Comparison between survival curves of HFD and control groups is performed with Mantel-Cox 
method. P values are presented on graphs.
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Figure 3. Elevated biomarkers and pathologic changes of the HFD-receiving AGMs that progressed to AIDS-like disease. HFD-receiving AGM HFD1 developed 
an AIDS-like disease, with distinctly elevated levels of HLA-DR and CD38 coexpressing CD8+ T cells in the intestine (A) and periphery (B), LPS (C), hyaluronic acid 
(D), sICAM-1 (E), and D-dimer (F), as compared with the remaining 3 AGMs on HFD. Ac, acute infection; BL, baseline (preinfection pre-HFD); Chr, chronic infection; 
Fat, preinfection post-HFD. Representative H&E images of lesions for AIDS and SIV-associated comorbidities from HFD1. (G) Enteritis, with disrupted intesti-
nal architecture, irregular crypts, enlarged villi, and alteration of the surface epithelium. (H) Numerous foamy macrophages in the lamina propria of the small 
intestine suggestive for active atypical mycobacterial disease. (I) Hepatic granulomas, suggestive of atypical mycobacterial disease. (J) Cystoisospora belli present 
in vacuoles in the intestinal epithelium. (K) Giemsa-staining confirmation of small intestine C. belli infection. (L) Eosinophil infiltration in the small intestine, 
characteristic for parasitic infections. (M) Colitis, with disrupted intestinal architecture, atrophic crypts and mononuclear cell infiltration of the mucosa, submuco-
sa, and of the muscle layers. (N) Upper panels: CMV immunohistochemistry, with positive cells in the colon. Lower panels: Numerous large cells in the lung, with 
nuclear and cytoplasmic viral inclusions characteristic for CMV infection (detail of O). (O) Interstitial pneumonia, with thickened alveolar walls due to infiltration 
with mononuclear cells. (P) Numerous microthrombi in the kidney glomeruli indicative of TMA (solid arrow). Disrupted kidney cortex architecture with irregular, 
small fibrotic glomeruli, pathognomonic for chronic glomerulonephritis (dashed arrow). (Q) Enlarged capillaries in the kidney parenchyma indicative of chronic 
stasis associated with heart failure. (R) Numerous hemosiderin-laden macrophages in the lung, indicative of chronic stasis associated with heart failure. Original 
magnifications: ×200 (G–I, M, and O–R); ×400 (L); ×600 (J, K, and N).
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TMA occurs in progressive HIV/SIV infections, where it is associat-
ed with increased levels of D-dimer (3). The AGM progressor had 
D-dimer levels in the range of PTMs with end-stage disease (Fig-
ure 3F). Chronic stasis (characteristic for congestive heart failure) 
was found in the liver, kidneys (Figure 3Q), and lungs (Figure 3R) 
and was characterized by dilated capillaries, increased blood con-
tent, and numerous hemosiderin-laden macrophages (Figure 3R).
HFD exacerbates systemic immune activation and inflammation. 
Immune activation and inflammation are hallmarks of chronic 
pathogenic HIV/SIV infections (1). As HFD also increases inflam-
mation independently (10), we next asked whether HFD and SIV 
infection can synergistically drive immune activation and inflam-
mation. While SIVsab-infected AGMs typically do not exhibit 
systemic immune activation and inflammation (1), the frequency 
of CD8+ (Figure 4A) and CD4+ (Supplemental Figure 3A) T cells 
expressing HLA-DR+ and CD38+ increased immediately in AGMs 
after starting the HFD, remaining significantly elevated through-
out the follow-up period, with the highest levels of CD38+ HLA-
DR+ T cells being observed in the AGM progressor (Figure 3, A 
and B). The Ki-67+ CD4+ T cells were also significantly increased 
during both acute and chronic infection (Supplemental Figure 3B) 
in HFD-receiving AGMs compared with controls.
SIV-infected PTMs receiving HFD similarly experienced a sig-
nificant increase of the HLA-DR+ CD38+ CD8+ T cells during both 
acute and chronic infection (Figure 4D).
The levels of the systemic inflammation biomarker C reac-
tive protein (CRP) were significantly higher in HFD-receiving 
SIV-infected AGMs and PTMs compared with controls (Figure 4, 
B and E). The levels of RANTES, a biomarker of macrophages 
and T cell recruitment at atherosclerotic lesion sites (27), were 
also significantly elevated compared with controls in both spe-
cies (Figure 4, C and F).
HFD induces inflammation and immune infiltration in the adi-
pose tissue. Adipose tissue is an important HIV reservoir (28). 
Prompted by our results showing both higher levels of cell- 
associated vRNA as well as vDNA and increased acute and chron-
ic immune activation and inflammation in the HFD-receiving 
NHPs, we further investigated the inflammatory status of the adi-
pose tissue. In SIV-infected PTMs, HFD was associated with more 
severe inflammatory infiltrates in the adipose tissue surrounding 
critical organs (GI tract and the heart), compared with SIV-infect-
ed controls. High-degree inflammatory infiltrates, represented by 
mononuclear cells, were observed in the peritoneal fat (Figure 5, 
left panel) and the epicardial adipose tissue (Figure 5, right pan-
el). Severe inflammatory infiltrates in the epicardium penetrat-
ed in the tunica adventitia of the adjacent coronary arteries. In 1 
HFD-treated PTM, inflammatory infiltrates penetrated the entire 
coronary wall, inducing significant damage and promoting leuko-
cyte adhesion (Figure 5, right panel, arrow).
Increased metabolic activity may be a source of the immune acti-
vation observed in HFD-receiving NHPs. Increased cell metabolism 
may drive immune activation. Using the seahorse technology, we 
assessed the impact of HFD on the metabolic status in PTMs and 
showed that HFD altered the PBMC metabolic state even before 
SIV infection. We quantified aerobic glycolysis by monitoring the 
extracellular acidification rate (ECAR) at basal respiration and in 
response to oligomycin (to measure ATP production), fluorocar-
bonyl cyanide phenylhydrazone (to measure maximal respiration), 
Figure 4. HFD induces elevated systemic immune activation and inflammation in SIV-infected NHPs. Frequencies of CD38 and HLA-DR coexpressing 
CD8+ T cells (A), CRP levels (B) and RANTES levels (C) to baseline levels in AGMs, as well as in PTMs (D–F), are compared at key time points of SIV infection 
within HFD group with Friedman test corrected for multiple comparisons, and between HFD and control groups with the Kruskal-Wallis test. Data are pre-
sented as individual values with medians. Sample size (n) and P values are presented on graphs. Ac, acute infection; BL, baseline (preinfection pre-HFD); 
Chr, chronic infection; Fat, preinfection post-HFD; Nx, necropsy.
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and rotenone addition (to measure nonmitochondrial respiration) 
(Supplemental Figure 4A). PBMCs collected after administering 
the HFD had significantly higher AUC of ECAR compared with 
PBMCs collected before HFD (Supplemental Figure 4B). The 
oxygen consumption rate (OCR) was also measured to quantify 
mitochondrial oxidative phosphorylation. After HFD, PBMCs had 
a trend of a lower OCR/ECAR ratio at basal respiration (Supple-
mental Figure 4C), indicating a metabolic shift toward aerobic 
glycolysis. After HFD, PBMCs also showed moderately increased 
maximal respiration OCR, spare respiratory capacity and ATP 
production, albeit without reaching significance (P > 0.1) (Supple-
mental Figure 4D). These results collectively indicate a post-HFD 
PBMC metabolic shift toward aerobic glycolysis, reflecting and 
contributing to a heightened activation status.
HFD compromises gut immune integrity, promoting microbial 
translocation. A major contributor to HIV-/SIV-related immune 
activation and inflammation is gut dysfunction and the conse-
quent microbial translocation (6). Because the HFD-induced 
changes could potentially disrupt the intestinal immune homeo-
stasis and epithelial barrier integrity, we next assessed HFD 
impact on the intestinal immune environment and microbial 
translocation. In HFD-receiving AGMs, intestinal CD4+ T cells 
were lost even before infection, yet without reaching statistical 
significance (P = 0.4029), probably due to limited sample size 
(Figure 6A). Similar to blood, this decrease was not due to CD4+ T 
cell downregulation (24), as no increase of the mucosal CD8-αlow/
CD4negCD8neg T cells occurred in the HFD-treated AGMs (data not 
shown). CD4+ T cell loss involved all memory subsets (Figure 6B). 
Intestinal CD4+ T cell recovery was minimal in chronically SIV- 
infected HFD-receiving AGMs (to 22.5% ± 4.5% of baseline lev-
els), while being moderate in controls (to 47.5% ± 5.9% of baseline 
levels) (Figure 6A), as reported (8). In PTMs, the magnitude of the 
SIVsab-induced mucosal CD4+ T cell depletion obscured any dif-
ference between HFD-treated PTMs and controls.
Among the mucosal CD4+ T cell subsets, Tregs showed a 
decreasing trend in HFD-fed AGMs even before infection (P = 
0.125) (Supplemental Figure 5A). In PTMs, mucosal CD4+ Tregs 
were significantly depleted throughout SIV infection (Supplemen-
tal Figure 5B), being significantly lower in the HFD-treated PTMs 
compared with controls during both acute and chronic infec-
tion. Treg decreases could diminish mucosal tolerance to intes-
tinal pathogens and disrupt local inflammation in the gut in the 
HFD-receiving NHPs (29).
HFD also induced increased activation of mucosal immune 
cells in HFD-receiving PTMs, with increases of Glut-1+ CD38+ 
HLA-DR+ CD4+ T cells (Figure 6C) and macrophage activation, 
indicated by the increased expression of CD80 (Figure 6D) and 
CD86 (Figure 6E), especially during chronic SIV infection.
Furthermore, HFD also significantly increased myeloper-
oxidase+ neutrophil infiltrates associated with more pronounced 
epithelial lesions and a higher frequency of crypt abscesses in 
chronically SIV-infected PTMs (Figure 7A), suggesting greater 
intestinal barrier damage and stronger inflammatory responses 
due to heightened microbial translocation.
Systemic biomarkers of microbial translocation and the asso-
ciated mucosal damage increased post-HFD administration. 
Plasma LPS levels increased in HFD-receiving AGMs during both 
acute and chronic SIV infection (Figure 7B) and were highest in 
the AGM progressor (Figure 3C). No differences in LPS levels were 
observed between the HFD-receiving and control PTMs, likely 
due to the massive SIV-induced intestinal damage, or to intrinsi-
cally elevated LPS levels in PTMs (30).
Additionally, intestinal fatty acid-binding protein (I-FABP), 
which is released by necrotic enterocytes, increased even prior SIV 
infection and remained increased throughout the follow-up in the 
HFD-receiving AGMs (Figure 7C). I-FABP was also significantly 
elevated in the HFD-receiving PTMs, especially during acute SIV 
infection and at the time of progression to AIDS (Figure 7D). These 
results demonstrate that HFD exacerbated intestinal dysfunction 
in both NHP models.
HFD induces pathological alterations of the liver. Previous stud-
ies showed that HFD affects liver integrity. In particular, HFD-in-
duced low systemic endotoxemia is responsible for NAFLD (31). 
In our study, steatohepatitis occurred in AGMs 82 days after HFD 
administration, prior to SIV infection (Figure 8A). Liver steatosis 
also occurred in all the HFD-receiving PTMs (Figure 8A) only 49 
days after HFD (at 9 dpi). Because these PTMs were at a very ear-
ly stage of SIV infection, NAFLD was due to diet rather than SIV 
infection. Conversely, NAFLD occurred in only a small fraction 
of controls and only during a late stage of SIV infection. The fat 
droplet infiltrates were diffusely distributed throughout the hepat-
ic lobules of the HFD-receiving PTMs (Figure 8A), whereas in con-
trols, they most frequently occurred at the periphery of the hepatic 
lobule, pathognomonic for hypoxia. The different distribution of 
fat accumulation in the liver points to different mechanisms for 
liver steatosis in chronically SIV-infected HFD-receiving PTMs 
and controls. NAFLD associated moderate sinusoidal fibrosis 
that became significant during chronic infection, as histological-
ly shown by collagen quantification (Figure 8B), and confirmed 
by measuring plasma hyaluronic acid (32), which significantly 
increased in HFD-receiving AGMs and PTMs compared with 
controls (Figure 8, C and D). Notably, the AGM progressor had 
Figure 5. HFD results in immune cell 
infiltration in adipose tissue in SIV- 
infected PTMs. Representative H&E 
images of peritoneal adipose tissue 
around GI tract (left panel) and epicar-
dial adipose tissue (right panels). Note 
prominent lymphocyte infiltration from 
the epicardial adipose tissue penetrating 
through the coronary wall indicated by 
the arrows. Original magnifications: ×200.
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In the pathogenic SIV infection of PTMs, which already asso-
ciates hypercoagulability (3), HFD administration did not further 
increase the oxidized HDL or sTF, but induced significantly higher 
FVII levels during SIV infection (Figure 9F). Furthermore, tropo-
nin-I was significantly elevated in 3 out of 5 chronically SIV-infected 
PTMs on HFD, while remaining undetectable in controls (Figure 
9G), directly confirming that HFD induced severe cardiac injury.
HFD increases the frequency and severity of CV lesions in SIV- 
infected PTMs. To assess the frequency of CV tissue lesions in 
HFD-treated NHPs, we conducted a histopathological diagnos-
tic on the necropsy samples collected from the PTMs. Although 
the CV lesions found in the HFD-treated PTMs were similar to 
those in chronic SIV-infected controls, they were more severe 
and occurred earlier (Supplemental Table 2). CV lesions included 
mononuclear cell infiltration in myocardium (Figure 10A) and epi-
cardium (Figure 10B), which formed lymphoid aggregates (Figure 
10C), severe myocardial cytolysis (Figure 10D), myocardial fatty 
infiltration (Figure 10E), and myocardial microthrombi (Figure 
10F). Two HFD-receiving PTMs had incipient aortic dissection 
(blood penetration underneath the endothelium) (Figure 10G). 
These lesions usually evolve into aorta aneurysms that may rup-
ture and induce fatal hemorrhages. Diffuse or localized myocardi-
al fibrosis also occurred (Figure 10H), as well as severe pericardial 
fibrosis, indicative of chronic pericarditis complicated with colla-
the highest levels of plasma hyaluronic acid (~5.5-fold increase 
from baseline) (Figure 3D), pointing to a significant role of HFD- 
induced liver pathology on the chronic SIV infection outcome.
HFD increases the risk of CV comorbidities in SIV-infected NHPs. 
HFD, especially with high saturated fat, is a major risk factor for CV 
disease (33). We investigated the effects of HFD on the coagulation 
status and CV health of SIV-infected NHPs, to assess the relative con-
tribution of dietary habits of the HIV-associated CV comorbidities.
The cholesterol (Figure 9A) and oxidized HDL (Figure 9B) 
levels increased in HFD-receiving, SIV-infected AGMs, while 
remaining virtually unchanged in controls. Oxidized HDL direct-
ly correlates with accelerated atherosclerosis (34); therefore, its 
post-HFD increase in SIV-infected AGMs (which do not develop 
CV disease) indicates harmful effects of HFD on CV health. Solu-
ble tissue factor (sTF) also increased in HFD-receiving, chronically 
SIV-infected AGMs (Figure 9C), pointing to activation of the extrin-
sic coagulation pathway and a higher thrombotic risk. The increased 
CV risk was also supported by significantly elevated levels of soluble 
p-selectin (Figure 9D) and soluble intercellular adhesion molecule-1 
(sICAM-1) (Figure 9E) throughout SIV infection in HFD-receiving 
AGMs compared with controls, demonstrating increased plate-
let and endothelial activation, along with increased immune cell 
recruitment to the blood vessel walls. The AGM progressor exhibit-
ed the highest sICAM-1 (Figure 3E), and D-dimer levels (Figure 3F).
Figure 6. HFD alters gut immune environment and activation states of the immune cells. (A) Mucosal CD4+ T cell depletion in HFD-receiving and control 
AGMs is shown as an index of baseline levels and compared at key time points of SIV infection within the HFD group with Friedman test corrected for mul-
tiple comparisons, and between HFD and control groups with Kruskal-Wallis test. (B) Mucosal-naïve, central memory, and effector memory CD4+ T cells are 
shown as an index of total baseline mucosal CD4+ T cell levels and compared before and after HFD in preinfection AGMs with Friedman test. Frequencies 
of Glut-1, HLA-DR, and CD38 coexpressing CD4+ T cells (C), as well as CD80-expressing (D) and CD86-expressing (E) macrophages in the intestine of PTMs 
are compared at key time points of SIV infection within HFD group with Friedman test corrected for multiple comparisons and between HFD and control 
groups with Kruskal-Wallis test. Data are presented as individual values with medians. Sample size (n) and P values are presented on graphs. Ac, acute 
infection; BL, baseline (preinfection pre-HFD); Chr, chronic infection; Fat, preinfection post-HFD.
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immune activation and inflammation are being extensively inves-
tigated. Thus, intestinal dysfunction was shown to play a central 
role in driving disease progression (and to be potentially driven) 
in addition to infection-related causes, by environmental factors, 
such as lifestyle and dietary intake. Little is known, however, about 
the synergy between HIV/SIV infection and environmental factors 
in driving pathogenesis.
Diet effects on HIV infection are difficult to study in humans, 
due to confounding factors (ART-related dyslipidemia and toxici-
ty, alcohol, tobacco and recreational drug use, sedentary lifestyle), 
and ethical limitations (experimental alterations of diet may have 
unknown effects, posing risks to human subjects; invasive sampling 
needed to assess diet effects on tissues is impossible in humans). 
NHPs may be employed to circumvent these ethical issues, while 
enabling the assessment of the impact of different dietary compo-
nents on SIV pathogenesis through administration of purified diets 
with a specific composition, staged introduction of various dietary 
elements, and testing in a strictly controlled environment.
Mansfield et al. previously reported that an atherogenic diet 
led to accelerated disease progression in rhesus macaques and 
highlighted the role of IL-18 in enhancing the disease onset (22). 
gen deposition (Figure 10I), which may restrict cardiac function. 
Myocardial trichrome quantification showed significant increased 
fibrosis of the cardiac muscle in the HFD-treated PTMs compared 
with controls (Figure 10, J and K). Incipient atherosclerosis lesions 
(fatty streaks) in coronaries, abdominal aorta, and carotid arteries 
were more frequent in the HFD-treated PTMs compared with con-
trols (Figure 10L). Fatty streaks were composed mainly by foamy 
cells (macrophages that engulfed cholesterol and triglycerides) 
and mononuclear cells, with T cells likely accumulating under-
neath the vascular endothelium (Figure 10L, left), resulting in a 
thickened blood vessel intima (Figure 10L, middle). Organized 
microthrombi that trigger additional leukocyte and platelet adhe-
sion also occurred in the HFD-treated animals (Figure 10L, right).
Discussion
Although the life span of HIV-infected subjects dramatically 
improved with ART, a higher mortality rate than in uninfected indi-
viduals still persists (2). Therefore, the study of non-AIDS comor-
bidities in long-term ART-suppressed subjects has gained traction 
(2). As promoters of non-AIDS comorbidities and the accelerated 
aging (5), the underlying mechanism(s) of HIV-/SIV-associated 
Figure 7. HFD induces intestinal epithelial barrier damage and increases microbial translocation. (A) Representative images of jejunum stained for 
myeloperoxidase (brown) collected before infection, at 9 days after infection, and at necropsy from contemporary controls and HFD-receiving PTMs. Note 
substantially increased myeloperoxidase underneath the damaged epithelium and adjacent to the crypt abscess. Original magnifications: ×200. Quan-
tification of the percent area of the jejunum positive for myeloperoxidase is shown in the right panel. Fold increase of LPS (B) and intestinal fatty-acid 
binding protein (C) to baseline levels in AGMs, as well as fold increase of intestinal fatty-acid binding protein (D) to baseline levels in PTMs are compared 
at key time points of SIV infection within HFD group with Friedman test corrected for multiple comparisons, and between HFD and control groups with 
Kruskal-Wallis test. Data are presented as individual values with medians. Sample size (n) and P values are presented on graphs. Ac, acute infection; BL, 
baseline (preinfection pre-HFD); Chr, chronic infection; Fat, preinfection post-HFD; Nx, necropsy.
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were also observed during acute SIV infection, when the viral reser-
voir was being seeded (36). This increased viral replication and res-
ervoir seeding observed in HFD-receiving NHPs may be driven by 
immune activation and inflammation and may point to a direct HFD 
impact on HIV/SIV replication and persistence. In turn, increased 
reservoir seeding during acute SIV infection may further boost sys-
temic immune activation and inflammation, creating a vicious cycle 
of accelerated disease progression in HFD-treated NHPs.
Adipose tissue is an important, yet neglected, reservoir for 
HIV/SIV (28). HFD administration induced prominent immune 
cell infiltration of the adipose tissue around the GI tract (perito-
neum) and heart (epicardium and pericardium), creating a proin-
flammatory environment favoring viral persistence and viscer-
al lesions. Through this mechanism, along with the cholesterol 
increases, HFD can increase viral reservoir size. As such, HFD 
may pose a particular threat to long-term suppressors and control-
lers by increasing the reservoir size, and thus dietary habits should 
be factored into HIV cure-related research.
We reasoned, however, that dietary effects on HIV/SIV pathogen-
esis and comorbidities are more profound and systemic, so we 
conducted a comprehensive assessment of the HFD effects on 
important organ systems, such as gut, liver, and the CV system.
We report that HFD administration to pathogenic (PTMs) 
and nonpathogenic (AGMs) models of SIVsab infection dramat-
ically affects SIV disease progression and survival. As for RMs 
(22), the HFD accelerated and exacerbated disease progression 
in PTMs. Surprisingly, HFD also induced progression to AIDS in 
an AGM. SIV disease progression is exceptional in natural hosts 
(35). For this reason, such a dramatic switch toward virulence sup-
ports a significant impact of dietary habits on SIV infection out-
come, strongly suggesting that diet may be used as an adjuvant to 
the treatment of HIV/SIV infection and, by extension, to chronic 
infectious diseases.
Notably, HFD increased viral replication in AGMs and PTMs, as 
illustrated by plasma VLs and cell-associated SIV RNA from PBMCs, 
LNs, and intestine. Increased levels of PBMC-associated SIV DNA 
Figure 8. HFD-induced liver steatosis and fibrosis in SIV-infected NHPs. Representative images of HFD-induced liver steatosis in AGMs and PTMs (A). 
Representative images of liver stained with Masson trichrome showing collagen (blue) collected before infection, at 9 days after infection, and at necropsy 
from control and HFD-receiving PTMs (B). Original magnifications: ×200. Quantification of the percent area of collagen is shown in the right panel. Fold 
increase of hyaluronic acid levels vs baseline levels in AGMs (C) and in PTMs (D) are compared at key time points of SIV infection within HFD group with 
Friedman test corrected for multiple comparisons and between HFD and control groups with Kruskal-Wallis test. Data are presented as individual values 
with medians. Sample size (n) and P values are presented on graphs. Ac, acute infection; BL, baseline (preinfection pre-HFD); Chr, chronic infection; Fat, 
preinfection post-HFD; Nx, necropsy.
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in this area, however, and future studies of larger cohorts may pro-
vide more insight into the influence of the HFD on the mucosal 
microbiome and the consequences on the gut health and the natu-
ral history of SIV infection of such changes.
Regardless of the mechanism, it is clear that increases in the 
gut damage induced by HFD boost systemic immune activation 
and inflammation, thus promoting HIV/SIV disease progression in 
the HFD-treated AGMs and PTMs.
Metabolic and liver pathology are understudied aspects of 
HIV/SIV pathogenesis, yet they may have a critical clinical impact 
on drug metabolism and long-term response to ART (42). HFD 
clearly induced significant liver pathology in both AGMs and 
PTMs, illustrated by the high-grade liver steatosis, sinusoidal 
fibrosis, and elevations of plasma biomarkers for liver fibrosis. 
This information demonstrates that the HFD used here is relevant 
and has effects comparable to the HFD of human subjects, which 
similarly rapidly develop NAFLD. Liver lesions were much more 
frequent in the HFD-receiving SIV-infected PTMs compared with 
controls, indicating a synergistic negative impact of SIV infection 
and dietary habits on the liver.
Consequential to both HFD-induced gut and liver pathology, 
the observed changes in coagulation markers, along with elevated 
HDL oxidation, strongly confirm that HFD poses a serious threat 
to CV health and mortality in SIV/HIV infections. Myocardial, peri-
cardial, and epicardial inflammation, myocardial cytolysis, micro-
thrombi formation, and myocardial fibrosis occurred early and were 
severe in HFD-receiving PTMs compared with chronic SIVsab- 
Local inflammatory infiltrates at multiple tissue sites contrib-
ute to the systemic immune activation and inflammation observed 
after HFD administration to SIV-infected NHPs and may explain 
the drastic CD4+ T cell loss, as well as the diminished chronic 
CD4+ T cell recovery observed in HFD-receiving AGMs. Muco-
sal CD4+ T cells normally recover in AGMs during chronic SIV 
infection (8). Consequently, our results suggest that diet may rep-
resent an overlooked contributor to the poor immune restoration 
in HIV-infected subjects on ART and should be integrated as a 
potential endpoint in trials aimed at controlling immune activa-
tion and inflammation and improving CD4+ T cell restoration.
Damage to the intestinal mucosa is also a major source of sys-
temic immune activation and inflammation in chronic and long-
term treated HIV/SIV infection. HFD induced significant changes 
in the intestinal immune environment and immune cell activation, 
promoting mucosal barrier destruction and increasing microbial 
translocation. Notably, Tregs were decreased in both HFD-receiv-
ing AGMs and PTMs, which may contribute to increased mucosal 
immune activation, inflammation, and autoimmunity (37).
Along with directly affecting the intestinal epithelium and 
shifting the mucosal environment toward a proinflammatory 
milieu (38), HFD may also have boosted the loss of total intestinal 
CD4+ T cells in HFD-receiving AGMs.
Based on previous literature (39–41), it is conceivable that the 
HFD also had an impact on the gut environment through changes 
in the microbiota. The very small sample sizes in our study pre-
vented enough statistical power to draw meaningful conclusions 
Figure 9. HFD increases thrombotic cardiovascular risk in SIV-infected NHPs. Serum cholesterol values (A), fold increase of plasma oxidized HDL (B), sol-
uble tissue factor (C), soluble p-selectin (D), and soluble ICAM-1 levels (E) to baseline levels in AGMs, as well as fold increase of factor VII levels to baseline 
levels in PTMs (F) are compared at key time points of SIV infection within HFD group with Friedman test corrected for multiple comparisons, and between 
HFD and control groups with Kruskal-Wallis test. (G) Plasma troponin-I levels during chronic infection in PTM are compared between HFD and control 
groups with Kruskal-Wallis test. Data are presented as individual values with medians. Sample size (n) and P values are presented on graphs. Ac, acute 
infection; BL, baseline (preinfection pre-HFD); Chr, chronic infection; Fat, preinfection post-HFD.
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able and documented by a plethora of tissue lesions. Meanwhile, in 
nonpathogenic infections of AGMs, HFD clearly affected canonical 
biomarkers of HIV/SIV pathogenesis and tissue pathology, and even 
induced disease progression characterized by alterations in the many 
predictor biomarkers of AIDS, multiple opportunistic infections, and 
comorbidities. SIV disease progression is extremely rare in AGMs 
(35). In our 20 years of studying hundreds of SIV-infected AGMs, this 
is the first instance in which we observed SIV disease progression in 
an AGM as a result of an experimental intervention (8, 35, 43). Our 
results indicate that the nonpathogenic models may be preferable to 
pathogenic models for studying the effects of diet on untreated SIV 
infection. Nevertheless, to model the majority of HIV-infected sub-
jects, in which the virus is therapeutically suppressed, and to investi-
gate the HFD-ARV interactions, SIV-infected PTMs on ART are the 
model of choice for our future studies.
infected controls. Most HFD-receiving PTMs also presented with 
incipient atherosclerosis (fatty streaks, foamy cells, and carotid inti-
ma thickening). These findings strongly imply an increased CV risk 
in HIV-infected subjects with unhealthy dietary habits.
Altogether, our results suggest that HFD may have a critical 
impact in disturbing the immunometabolic axes between gut, liv-
er, and the CV system by inducing lesions and proinflammatory 
responses at all these sites.
Notably, the HFD effects on SIV pathogenesis were more clear 
cut in AGMs than in PTMs, likely due to the nature of SIV infection in 
the 2 models. The very severe features of untreated SIV infection in 
PTMs (massive and dramatic CD4+ T cell depletion, high and intrin-
sic microbial translocation [ref. 30], chronic immune activation and 
inflammation), likely masked the more subtle effects of diet. Never-
theless, the HFD deleterious effects on PTM survival were indisput-
Figure 10. HFD increases severity of CV lesions 
in SIV-infected PTMs. Representative H&E 
images of (A) myocardial and (B) epicardial 
immune infiltration, (C) lymphoid aggregates 
in epicardium, (D) myocardial cytolysis, (E) 
myocardial fatty infiltration (arrows), (F) micro-
thrombi (arrows), (G) aortic dissection, (H) myo-
cardial and (I) pericardial fibrosis in HFD-receiv-
ing PTMs. (J) Representative trichrome-stained 
images of cardiac fibrosis observed in 
HFD-receiving infected PTMs compared with 
control-infected and SIV– PTMs. Quantification 
of the percent area of collagen is shown in (K). 
Data were compared with Kruskal-Wallis test 
corrected for multiple comparisons and are 
presented as individual values with median. 
Sample size (n) and P values are presented 
on graphs. SIV–, preinfection pre-HFD; SIV+, 
chronic infection without HFD; HFD SIV+, chronic 
infection with HFD. (L) Representative H&E 
images of signs of evolving atherosclerosis with 
organized thrombus in HFD-receiving PTMs. 
Original magnifications: ×200.
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At necropsy, numerous tissues were collected from both HFD-fed 
and chow-fed PTMs: gut, LNs, liver, lungs, kidneys, heart, aortas, cor-
onaries, brachial, and carotid arteries.
In HFD-receiving AGMs (Figure 1), blood and LNs were collected 
pre-HFD/pre-SIV infection, at 102 days post-HFD/pre-SIV infection, 
during acute (9 dpi) SIV infection, and during chronic infection (≈100 
dpi). Intestinal and liver resections were performed pre-HFD/pre-SIV 
infection, and at 82 days post-HFD/pre-SIV infection. Only 1 of the 
HFD-fed AGMs was euthanized during the follow-up, from which we 
collected the same tissues as from PTMs.
All AGM controls (Figure 1) were historical and followed an iden-
tical blood and LN sampling schedule as the HFD-receiving AGMs, 
except for the post-HFD/pre-SIV infection point. No gut and liver 
resections were performed in control AGMs.
Tissues collected at necropsy were fixed in 10% buffered forma-
lin, embedded in paraffin, and cut into 4-μm sections for staining.
To reflect the differences in sampling between historical and con-
temporary controls, for each measurement, the exact number of ani-
mals is indicated in the figures or figure legends.
Flow cytometry analysis. Whole blood or mononuclear cells isolat-
ed from blood and intestinal samples were stained for flow cytome-
try, as described (25, 43). The mAbs are summarized in Supplemen-
tal Table 3. All Abs were validated and titrated using AGM and PTM 
PBMCs (25, 43). Stained cells were analyzed with an LSRII flow 
cytometer (BD Biosciences) and FlowJo Version 7.6 software (TreeS-
tar). Gating strategies for immune cell populations and their activation 
status are described in the Supplemental Materials. Some flow cytom-
etry stainings, such as Glut-1, CD80, CD86, IL-17, FoxP3, and CD25, 
were not done in the historical controls because they were not part of 
the original design of the studies including those animals. To avoid 
comparisons between stainings performed on fresh and frozen cells, 
we used only the flow cytometry results obtained on fresh samples 
(2-hour intervals after blood collection). Sample size is indicated for 
each measurement in the figures and figure legends.
Viral quantification. SIV pVLs were quantified using an SIVsab-spe-
cific quantitative real-time PCR (43). Cell-associated vRNA and vDNA 
were quantified by quantitative PCR (q-PCR). Total RNA was extract-
ed from cell pellets using a TRIzol-based protocol (45). The DNA 
phase was extracted by adding 500 μL of DNA extraction solution (4M 
Guanidine Thiocyanate, 50 mM sodium citrate NaCi, 1-M Tris) (45). 
Extracted plasma RNA samples were reverse-transcribed, and cDNAs 
and vDNAs were quantified by q-PCR using long terminal repeat–spe-
cific primers and a labeled probe (43). To assess the sample cell counts, 
CCR5-specific primers were used, and the final number of vRNA and 
vDNA copies was divided by the number of cells present in the sample 
to establish the number of vRNA copies/million cells.
CMV plasma VLs were quantified as follows: CMV genomic DNA 
was extracted from 400 μl of plasma using QIAmp DNA Mini kit (Qia-
gen). CMV DNA was quantified by q-PCR using the forward primer 
(5′-GTT TAG GGA ACC GCC ATT CTG-3′, the reverse primer 5′-GTA 
TCC GCG TTC CAA TGC A-3′, and the probe 5′ 6FAM/TCC AGC 
CTC/ZEN/CAT AGC CGG GAA GG/3′IABkFQ, designed to recog-
nize a region of 108 bp in the immediate early gene of CMV (46).
Ten microliters of the plasma eluate was added to a PCR mix con-
taining 300 nM of forward and reverse primer, 100 nM of probe, and 25 
μl of TaqMan Gene Expression Master Mix (Thermo Fisher Scientific). 
The cycling parameters were 95°C for 5 minutes, followed by 45 cycles 
In conclusion, we demonstrated for the first time an important 
role of HFD in promoting the viral reservoir seeding and profound 
alterations of the gut mucosal integrity as well as hepatic and CV 
pathology. These features had a significant impact on SIV disease 
progression, development of comorbidities, and survival in both 
pathogenic and nonpathogenic SIV infections. We therefore pro-
pose a paradigm in which, through multiple pathological path-
ways, HFD accelerates SIV disease progression.
In the post-ART era, the major concerns in long-term virally 
suppressed subjects are no longer viral replication and disease 
progression. Instead, these issues comprise the non-AIDS comor-
bidities, residual immune activation and inflammation, and reser-
voir persistence. Our study strongly supports accounting for diet 
and other behavioral factors in future strategies aimed at reducing 
comorbidities, inducing functional cure and improving the quality 
of life for HIV-suppressed patients.
Methods
Animals, infection, and diet. Thirteen AGMs and 15 PTMs were infect-
ed with i.v. plasma equivalent to 300 tissue culture infectious doses 
(TCID50) of SIVsab (25, 43). For AGM infection, we used SIVsab92018 
(43), a plasma stock containing a diverse swarm of transmitted-found-
er SIVsab strains, collected from an acutely infected AGM (44). PTM 
infection with SIVsab92018 ranges from rapid progression to virus 
control (25). Therefore, PTMs were infected with plasma from an 
SIVsab92018-infected rapid progressor PTM (SIVsabBH66) (25), then 
passaged in a naïve PTM, and collected at the viral peak. Thus, SIVsab-
BH66 contains transmitted-founder variants, while showing consistent 
high viral replication and pathogenicity in PTMs. The sequences of these 
2 stocks are very similar, and the sole reason for using different stocks in 
the 2 species is the need for consistent viral replication.
The animal groups are described in the Results section, under the 
Study Design heading.
Commercially available primate HFD (Custom Diet 5A1F, Test Diet) 
and normal chow (ND) (Monkey Diet no. 5038, Lab Diet) were used 
for HFD and control groups, respectively. HFD and ND compositions 
are detailed in Table 1. The HFD group received higher amounts of fat, 
much higher cholesterol content, a higher linoleic acid (omega-6 fatty 
acid) to linolenic acid (omega-3 fatty acid) ratio, and lower amounts of 
other omega-3 fatty acids, being therefore rich in several categories of fat 
dietary components reported as detrimental for human health.
Sample collection. Blood, LN, intestinal, and liver resections were 
collected and processed as described (8, 43). Collection and process-
ing were similar for all the NHPs.
For HFD-receiving PTMs (Figure 1), blood and LNs were collect-
ed pre-HFD/pre-SIV infection, at 39 days post-HFD/pre-SIV infection, 
during the acute SIV infection (9 dpi), chronic infection (≈100 dpi), and 
at necropsies (128–218 dpi). Additional blood samples were collected at 
necropsy. Intestinal and liver resections were performed pre-HFD/pre-
SIV infection and at 48 days post-HFD, during the acute SIV infection (9 
dpi). Additional gut and liver samples were collected at necropsy.
The blood sampling schedule for both contemporary and histori-
cal PTM controls (Figure 1) was identical to the HFD-receiving PTMs, 
except for the post-HFD/pre-SIV infection time point. Gut and liver 
sampling were similar in the contemporary controls to HFD-receiving 
NHPs. Intestinal and liver resections were not performed in the his-
torical controls.
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Statistics. All statistical analyses were performed using Prism 5.0 
software (GraphPad Software) and R (R Foundation for Statistical 
Computing, Vienna, Austria). Data are represented as individual val-
ues with medians, unless otherwise specified. Due to the relatively 
small size of the groups and individual variations between NHPs, for 
some parameters we used baseline levels (average of 3 different time 
points collected before both HFD and SIV infection) to normalize the 
results as fold change from the baseline. Different time points for the 
HFD group (pre-, post- HFD, acute and chronic SIV) were matched 
within animals, and comparisons were made using the Friedman test 
(for 1-way repeated measurements by rank) with post hoc comparisons 
with baseline corrected for multiple comparisons (51, 52). Compari-
sons for the same time point between the independent samples of the 
HFD and control groups were performed with the Kruskal-Wallis test. 
Survival was estimated by the Kaplan-Meier estimator, and compared 
between groups with the Mantel-Cox method. P values less than 0.05 
were considered significant.
Study approval. This study was reviewed and approved by the 
Institutional Animal Care and Use Committee (protocols no. 12121250 
and no. 14043645) of the University of Pittsburgh at Pittsburgh, Penn-
sylvania, USA.
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of amplification at 95°C for 15 seconds and 1 minute at 60°C. CMV DNA 
quantification was performed using 10-fold serial dilution of a plasmid 
containing the entire rhesus CMV immediate-early gene (46).
For the detection of CMV in tissues, the DNA was extracted from 
the snap-frozen tissues by TRIzol isolation (Sigma-Aldrich), and 700 
ng of total nucleic acid was then subjected to PCR using the primers 
and conditions employed in the real-time PCR assay.
Histological analysis. Gut, LNs, liver, lungs, brain, kidneys, heart, 
aortas, coronaries, and carotids collected at the necropsy were first 
stained with H&E for routine histopathology (3). Infection with 
Cystoisospora belli was confirmed by Giemsa stain (47). The degree of 
liver and heart fibrosis was assessed by Masson trichrome (3). Immuno-
histochemistry was performed as described in the Supplemental Mate-
rial (8, 45) to assess neutrophil infiltration and for CMV detection. Slides 
were visualized with a Carl Zeiss Axio Imager M1 microscope using the 
following objectives: ×10 /0.3 DICI Plan Neofluar, ×20 /0.8 DICII Plan 
Apochromat, and ×40 /0.75 DICII Plan Neofluar. Micrographs were 
taken with a Carl Zeiss AxioCam MRc5. Images were acquired and ana-
lyzed using Carl Zeiss Axio Vision SE64 Release 4.8.2. Quantification 
was performed using open-source FIJI image software using 10 images 
per section/time point/animal. The positive signal was isolated via color 
threshold, and the percent area positive was measured and averaged.
Measurement of plasma/serum-based biomarkers. Microbial transloca-
tion was monitored by testing the plasma LPS levels with Limulus Ame-
bocyte Lysate assay (Lonza), according to the manufacturer’s protocol. 
Intestinal FABP (I-FABP) (48), was measured with a monkey I-FABP ELI-
SA kit (MyBioSource, Inc.) (48). Plasma hyaluronic acid levels (32) were 
measured with Monkey Hyaluronic Acid ELISA kit (MyBioSource).
Inflammatory cytokines and chemokines were monitored in 
plasma (45), using the Cytokine Monkey Magnetic 29-Plex Panel 
(Invitrogen), as per manufacturer’s instruction. Results were read by 
a Bio-Plex reader (Bio-Rad Laboratories), using Luminex technology 
(Luminex Corporation). CRP was tested using a monkey CRP ELISA 
Kit (Life Diagnostics) (45).
Coagulation status was assessed using multiple biomarkers asso-
ciated with hypercoagulation in humans (49). TF levels were mea-
sured with IMUBIND Tissue Factor ELISA (Sekisui Diagnostics, LLC). 
D- dimer was measured using a STAR automated coagulation analyzer, 
(Diagnostica Stago) and an immunoturbidimetric assay (Liatest D-DI; 
Diagnostica Stago) (3). Prompted by our previous study showing that TF 
pathway may be critical in bridging hypercoagulation and inflammation 
in HIV/SIV pathogenesis (20), we measured the plasma levels of factor 
VII using a commercially available ELISA assay (Affinity Biologicals).
To evaluate the CV risk, serum lipid composition was also assessed 
by measuring cholesterol (Marshfield Labs), oxidized HDL in plasma 
with OxiSelect Human Oxidized HDL ELISA kit (Cell Biolabs, Inc.). Tro-
ponin-I, a biomarker of cardiac stress, which is elevated in chronically 
HIV-infected subjects (50), was measured with ultrasensitive monkey 
cardiac troponin-I ELISA (Life Diagnostics). Platelet and endothelial acti-
vation were assessed by measuring the plasma levels of soluble p-selectin 
(Platinum ELISA, eBioscience, Inc.) and soluble ICAM-1 (ICAM-1 Mon-
key Instant ELISA Kit, Thermo Fisher Scientific).
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